EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients

URN to cite this document:: urn:nbn:de:bvb:355-epub-521134
DOI to cite this document:: 10.5283/epub.52113

Mederer, Tobias ; Elsner, Felix ; Robold, Tobias ; Großer, Christian ; Neu, Reiner ; Ried, Michael ; Bleicher, Sabine ; Schamberger, Thomas ; Blochberger, Isabell ; Hofmann, Hans-Stefan ; Klein, Christoph A.

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(673kB)

Date of publication of this fulltext: 07 Apr 2022 04:48

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Introduction: Detection of disseminated cancer cells (DCC) in bone marrow (BM) of patients with early-stage NSCLC has been associated with poor outcome. However, the phenotype, and hence relevant therapy targets, of DCCs in BM are unknown. We therefore compared a classical pan-Cytokeratin (CK) antibody for DCC detection with an anti-EpCAM antibody that may also detect more stem-like cells and ...